Investor Relations

Boston Therapeutics to Sponsor Symposium at American Chemical Society's Fall National Meeting in San Francisco

Download PDF

Company Will Sponsor "Rearrangement and Domino Reactions in Carbohydrate Chemistry" Symposium Organized by Division of Carbohydrate Chemistry

MANCHESTER, NH -- (Marketwired) -- 07/30/14 -- Boston Therapeutics, Inc. (OTCQB: BTHE), a developer of complex carbohydrate therapeutics to treat diabetes, is sponsoring a symposium to be held at the American Chemical Society's Fall National Meeting in San Francisco on Monday, August 11.

The symposium, titled "Rearrangement and Domino Reactions in Carbohydrate Chemistry," is being organized by the American Chemical Society's Division of Carbohydrate Chemistry. The symposium will highlight recent developments that make the employment of a novel methodology for connecting molecules, via domino-rearrangement reactions, exceptionally successful and important in studies related to the discipline of glyco-science.

Zbigniew J. Witczak, Ph.D., co-organizer of the Symposium and Chair of the Department of Pharmaceutical Sciences at Wilkes University, said, "The research Boston Therapeutics is conducting in the area of carbohydrate chemistry is indicative of the important role of this subject in medical research today. We are looking forward to sharing these insights with our peers."

David Platt, Ph.D., Chief Executive Officer of Boston Therapeutics, said, "Our success to date in harnessing carbohydrate chemistry in drug development reflects the relevance of this branch of science. We are enthusiastic about fostering further innovation in the field and believe symposia like this one are positive ways to communicate new results."

About Boston Therapeutics, Inc.

Boston Therapeutics, headquartered in Manchester, NH, (OTCQB: BTHE) is an innovator in designing compounds using complex carbohydrate chemistry. The company's product pipeline is focused on developing and commercializing therapeutic molecules that address diabetes and inflammatory diseases, including: BTI-320, a new generation of Alpha Glucosidase Inhibitor, is a non-systemic chewable therapeutic compound designed to reduce post-meal glucose elevation. The Company is currently enrolling patients in a Phase IIb clinical study with BTI-320 in patients with type 2 diabetes. IPOXYN is an injectable anti-necrosis drug designed initially to treat lower limb ischemia associated with diabetes and is pre-clinical. The company produces and sells SUGARDOWN®, a non-systemic complex carbohydrate-based dietary food supplement designed to support healthy blood glucose. More information is available at

Cautionary Note Regarding Forward Looking Statements

This press release contains, in addition to historical information, forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements relate to future events or future financial performance, and use words such as "may," "estimate," "could," "expect" and others. They are based on our current expectations and are subject to factors and uncertainties which could cause actual results to differ materially from those described in the statements. Factors that could cause our actual performance to differ materially from those discussed in the forward-looking statements include, among others, that our plans, expectations and goals regarding the clinical trials are subject to factors beyond our control and provide no assurance of FDA approval of any of our future drug development plans. Our clinical trials may not produce positive results in a timely fashion, if at all, and any necessary changes during the course of the trial could prove time consuming and costly. We may have difficulty in enrolling candidates for testing, which would affect our estimates regarding timing, and we may not be able to achieve the desired results. Any significant delays or unanticipated costs in any subsequent drug trial could delay obtaining meaningful results from Phase II studies and/or preparing for Phase III studies with the current cash on hand.

Upon receipt of FDA approval, we may face competition with other drugs and treatments that are currently approved or those that are currently in development, which could have an adverse effect on our ability to achieve revenues from our approved products. Plans regarding development, approval and marketing of any of our compounds, including BTI-320, are subject to change at any time based on the changing needs of our company as determined by management and regulatory agencies. We have incurred operating losses since our inception, and our ability to successfully develop and market drugs may be affected by our ability to manage costs and finance our continuing operations. For a discussion of additional risk and other factors affecting our business, see our Annual Report on Form 10-K for the year ended December 31, 2013, and our subsequent filings with the SEC. You should not place undue reliance on forward-looking statements, and actual results may differ materially from the results anticipated in our forward-looking statements. Although subsequent events may cause our views to change, we disclaim any obligation to update forward-looking statements.

© Boston Therapeutics, Inc. All rights reserved.


Boston Therapeutics, Inc.
Anthony Squeglia
Chief Financial Officer
Phone: 603-935-9799

Source: Boston Therapeutics